Next 10 |
2024-04-24 15:12:02 ET CureVac N.V. (CVAC) Q4 2023 Earnings Conference Call April 24, 2024 09:00 AM ET Company Participants Sarah Fakih - Vice President of Corporate Communications & Investor Relations Alexander Zehnder - Chief Executive Officer Myriam Mendil...
Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary s...
Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas TÜBINGEN, GERMA...
2024-04-23 14:08:22 ET More on CureVac BV CureVac: No Momentum In Sight CureVac, MD Anderson team up for cancer vaccines CureVac posts early efficacy results for GSK-partnered flu shot Seeking Alpha’s Quant Rating on CureVac BV Historical earni...
2024-04-23 10:25:34 ET Major earnings expected before the bell on Wednesday include: The Boeing ( BA ) Biogen ( BIIB ) General Dynamics ( GD ) AT&T ( T ) Thermo Fisher Scientific ( TMO ) Read the full article on Seeking Alpha For f...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business up...
2024-04-17 17:01:03 ET Gainers: Vanda Pharmaceuticals ( VNDA ) +7% . Sutro Biopharma ( STRO ) +5% . CureVac ( CVAC ) +5% . CorMedix ( CRMD ) +4% . Bank OZK ( OZK ) +4% . Losers: Omega Therapeutics ( OM...
2024-04-16 07:59:04 ET More on CureVac BV CureVac: No Momentum In Sight CureVac posts early efficacy results for GSK-partnered flu shot Seeking Alpha’s Quant Rating on CureVac BV Historical earnings data for CureVac BV Financial information for...
Agreement creates strong synergies between CureVac's unique end-to-end mRNA capabilities and MD Anderson's translational and clinical research expertise Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet ...
2024-04-04 08:20:35 ET More on CureVac BV CureVac: No Momentum In Sight Seeking Alpha’s Quant Rating on CureVac BV Historical earnings data for CureVac BV Financial information for CureVac BV Read the full article on Seeking Alpha For f...
News, Short Squeeze, Breakout and More Instantly...
CureVac N.V. Company Name:
CVAC Stock Symbol:
NASDAQ Market:
Canadian Biotech company Acuitas Therapeutics and Germany-based CureVac NV (NASDAQ:CVAC) have settled Acuitas’ lawsuit ov...
Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary s...
Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas TÜBINGEN, GERMA...